EcoDrugPlus

Epidermal Growth Factor Receptor A (Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog, Avian)

Ensembl ID : ENSAPEG00000024805
Gene Symbol: EGFRA
1 Cross references
212 Possible Orthologues:

Epoxide Hydrolase 2, Cytoplasmic

Ensembl ID : ENSAPEG00000007677
Gene Symbol: EPHX2
1 Cross references
204 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSAPEG00000012879
Gene Symbol: ERBB2
1 Cross references
200 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSAPEG00000016343
Gene Symbol: ERBB3
1 Cross references
210 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3b

Ensembl ID : ENSAPEG00000002872
Gene Symbol: ERBB3B
1 Cross references
207 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSAPEG00000014144
Gene Symbol: ERBB4
1 Cross references
222 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4a

Ensembl ID : ENSAPEG00000012873
Gene Symbol: ERBB4A
1 Cross references
242 Possible Orthologues:

Estrogen Receptor 1

Ensembl ID : ENSAPEG00000016404
Gene Symbol: ESR1
1 Cross references
215 Possible Orthologues:

Estrogen Receptor 2a

Ensembl ID : ENSAPEG00000006416
Gene Symbol: ESR2A
1 Cross references
199 Possible Orthologues:

Estrogen Receptor 2b

Ensembl ID : ENSAPEG00000003028
Gene Symbol: ESR2B
1 Cross references
207 Possible Orthologues:

Estrogen-Related Receptor Gamma A

Ensembl ID : ENSAPEG00000003311
Gene Symbol: ESRRGA
1 Cross references
203 Possible Orthologues:

Exportin 1

Ensembl ID : ENSAPEG00000006583
Gene Symbol: XPO1
1 Cross references
229 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).